Completed PHASE3 INTERVENTIONAL NCT00150410

Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose

A One-Year, Open, Randomized, Parallel, Three-Arm Study Comparing Exubera® (Insulin Dry Powder Pulmonary Inhaler) vs. Avandia® (Rosiglitazone Maleate) as Add-On Therapy vs. Exubera® Substitution of Sulfonylurea in Patients With Type 2 Diabetes, Poorly Controlled on Combination Sulfonylurea and Metformin Treatment

Sponsor: Pfizer

Conditions Diabetes Mellitus

Interventions Inhaled insulin

Updated 6 times since 2017 Last updated: Oct 28, 2008 Started: Jan 31, 2003 Completion: Jun 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00150410, this PHASE3 trial focuses on Diabetes Mellitus and remains completed. Sponsored by Pfizer, it has been updated 6 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer
Sanofi

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Albuquerque, United States , Alhambra, United States , Atlanta, United States , Augusta, United States , Baltimore, United States , Baton Rouge, United States , Box Hill, Australia , Butte, United States , Camperdown, Australia and 89 more locations